Targeting Unc-51 Like Autophagy Activating Kinase 1 (ULK1) in Acute Myeloid Leukemia (AML)

AML, autophagy inhibition, combination therapy, ROS, DNA damage
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research

Related Links:

ConclusionsrAML remains a clinical challenge. Genetic variability in outcomes was observed. A majority of patients with inv(16) were successfully salvaged post relapse while patients with 11q23 rearrangement had a poor prognosis. Only a third of those with t(8;21) rAML survived. Better access to SCT in HIDC is needed.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionOur study confirms the high prevalence of AML in elderly patients with generally poor outcomes. Selected patients with a good performance status and those who received intensive induction treatment could have a long-term survival.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
The outcome of childhood acute myeloid leukemia in first relapse (rAML) remains poor. Reported overall survival (OS) rates vary between high-income developed countries and those with fewer resources. The OS of rAML in high-income developing countries (HIDC) has not been reported.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
This study evaluated the impact of HDAC consolidation cycles before allo-HCT on 194 patients with AML in first complete remission between 1998 and 2014. The patients were reclassified into three groups: no consolidation (C0, n=20), 1 consolidation (C1, n=115), and ≥2 consolidations (C2, n=59) by the pre-HCT consolidation cycles. The 3-year relapse-free survival (RFS) was 45.9%, 66.9%, and 73.3% for the C0, C1, and C2 groups, respectively (P=0.064), while the 3-year overall survival rate was 35.0%, 55.2%, and 67.5%, respectively (P=0.106). The cumulative incidence of acute graft-versus-host disease (GVHD) was higher in t...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionsThe rate of complete response after the first course of induction therapy was significantly higher among adult patients with AML who received IDA as a part of induction therapy compared with those who received HDD.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
AbstractIt is well established that some rheumatic syndromes (RS) are associated with several hematological malignancies. We aimed to describe the clinical course of patients with hematological malignancies mimicking RS. We studied a series of four patients presenting with apparent RS who were eventually diagnosed with hematological malignancies, and reviewed the relevant literature. Our series consisted of 4 patients, with a mean age of 62.8  ± 20.3 years, who presented to our rheumatology unit between December 2012 and March 2018. Two patients were initially diagnosed with polyarthritis. One of these...
Source: Rheumatology International - Category: Rheumatology Source Type: research
ConclusionOur study confirms the high prevalence of AML in elderly patients with generally poor outcomes. Selected patients with a good performance status and those who received intensive induction treatment could have a long-term survival.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Elderly patients with acute myeloid leukemia (AML) have a poorer prognosis than younger patients from previous studies. This 3-year multicenter study was conducted on elderly Thai patients with AML, and aimed to evaluate the epidemiology and factors impacting the survival outcome of the patients. From the 235 elderly patients with AML, patients with poor performance status and patients receiving low-intensive therapy had significantly poorer survival outcome.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Publication date: Available online 4 August 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kiyomi Mashima, Iekuni Oh, Takashi Ikeda, Yumiko Toda, Shoko Ito, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Kaoru Morita, Ryoko Yamasaki, Yasufumi Kawasaki, Miyuki Sugimoto, Chihiro Yamamoto, Masahiro Ashizawa, Shin-Ichiro Fujiwara, Kaoru Hatano, Kazuya Sato, Ken Omine, Kazuo Muroi, Yoshinobu KandaAbstractBackgroundWT1 mRNA expression is a universal marker of MRD in patients with acute myeloid leukemia (AML). The aim of this retrospective study was to evaluate the ability of serial measurement of peripheral blood ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 13 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Marielle Perry, Sarah Bertoli, Clément Rocher, Sandrine Hayette, Sophie Ducastelle, Fiorenza Barraco, Hélène Labussière-Wallet, Gilles Salles, Christian Recher, Xavier Thomas, Etienne PaubelleAbstractBackgroundOutcome of patients with mutation of the FLT3 tyrosine kinase domain (FLT3-TKD) in acute myeloid leukemia (AML) remains controversial.Patients and MethodsHerein, we present a retrospective study of 126 newly diagnosed patients with AML performed in 2 French centers.ResultsFLT3-TKD mutati...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Leukemia | Lymphoma | Myeloma